Contact: Chris Martin, IASLC Media Relations, firstname.lastname@example.org, 630.670.2745
VIENNA, Austria (August 6, 2022) ⎯ Dr. Edward Patz was awarded the Joseph W. Cullen Prevention & Early Detection Award today at the 2022 IASLC World Conference on Lung Cancer.
The Joseph W. Cullen Prevention/Early Detection Award recognizes an IASLC scientist for lifetime achievement in the prevention of thoracic malignancies. Dr. Cullen served as the Deputy Director of the National Cancer Institute’s (NCI) Division of Cancer Prevention and Control. He created the Smoking, Tobacco and Cancer Program at the NCI in 1982.
Dr. Patz is a thoracic radiologist with a long-standing interest in early lung cancer detection, molecular diagnostics, and novel therapeutic strategies. He has been studying lung cancer for over 25 years and has been involved in numerous clinical trials, including the National Lung Cancer Screening Trial (NLST). Dr. Patz was on the ACRIN- NLST Executive Committee and was the chair of the ACRIN-NLST Biomarker Committee. His basic science laboratory projects focus on the clonal evolution of tumors, cell-free plasma DNA as biomarkers for early detection, and the role of inflammation in cancer. His work has resulted in several seminal publications.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2022.iaslc.org/.